Skip to main content
Clinical Trials/CTRI/2024/09/074468
CTRI/2024/09/074468
Not yet recruiting
Phase 4

Effect of granulocyte colony stimulating factor (G-CSF) in prevention of radiation induced oral mucositis in patients receiving chemo-radiotherapy for head and neck cancer.

VMMC and Safdarjung hospital1 site in 1 country70 target enrollmentStarted: October 22, 2024Last updated:

Overview

Phase
Phase 4
Status
Not yet recruiting
Sponsor
VMMC and Safdarjung hospital
Enrollment
70
Locations
1
Primary Endpoint
To ascertain the efficacy of granulocyte-colony stimulating factor (G-CSF) by

Overview

Brief Summary

It is an interventional study. Patients will have to give detailed clinical history and undergo clinical examination with evaluation of the primary tumour, nodes and metastasis. Radiation dose will be 66-70 Gy as total dose, with 2Gy in each fraction given over 5 consecutive days. Chemotherapy will be given as weekly intravenous cisplatin (40mg/m2) as per standard protocol. Patients who have received radiation dose of 10 Gy, will be administered 2µg/kg/day subcutaneously of granulocyte-colony stimulating factor (G-CSF) in the unirradiated normal skin daily till the end of radiation therapy. Patients will be assessed with daily clinical examination, to grade oral mucositis using RTOG criteria(8), and weekly blood tests.

Study Design

Study Type
Interventional
Allocation
Na
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 70.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Patients having age more than 18 years, and are histologically proven case of squamous cell carcinoma of head and neck with ECOG performance status of 0-
  • Patients who have received a radiation dose of 10Gy to head and neck area during current chemo-radiotherapy treatment.

Exclusion Criteria

  • Patients with recurrent or metastatic disease or second primary.
  • Prior irradiation to head and neck area.
  • History of anaphylaxis to G-CSF injection.

Outcomes

Primary Outcomes

To ascertain the efficacy of granulocyte-colony stimulating factor (G-CSF) by

Time Frame: weekly during the course of radiation therapy

studying the incidence of grade III/IV oral mucositis, using RTOG criteria

Time Frame: weekly during the course of radiation therapy

Secondary Outcomes

  • To study the time of onset & duration for healing of grade III & IV oral mucositis.(Weekly during the course of radiation therapy)

Investigators

Sponsor
VMMC and Safdarjung hospital
Sponsor Class
Research institution and hospital
Responsible Party
Principal Investigator
Principal Investigator

DEVAL GUPTA

VMMC AND Safdarjung hospital

Study Sites (1)

Loading locations...

Similar Trials